AzTrials
AzTrials

Peripheral Vascular Disease PatientPhase 3NCT02624674

Multi-spectral Imaging to Assess Wounds in Peripheral Vascular Disease Patients

A Phase 3 study testing Multi-spectral Imaging Device (MSID) in people with Peripheral Vascular Disease Patient, run by Unity Health Toronto.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Peripheral vascular disease (PVD) is a common disease of impaired blood flow resulting in the compromised tissue perfusion of lower limbs. PAD patients can experience pain, diminished exercise capacity, and tissue loss, with some ultimately requiring amputation. The economic burden of PVD is significant. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Peripheral Vascular Disease Patient
What is being tested?
Multi-spectral Imaging Device (MSID)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
No sites listed yet
Study dates
Dec 2015to Dec 2016
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Lower extremity wound from peripheral vascular disease, which has had optimum multi-disciplinary team management for >4 weeks
  • Wound size of <10 cm
  • In-patients or out-patients in the care of St.Michael's Hospital (SMH) wound care team
  • Patients aged >18 years
  • Patients who understand the study, agree to adhere to the treatment and are able to give consent
  • Patients who can be followed by the same investigating team for the whole period of their participation in the study
Show all 15Show fewer
  • 3.3 Exclusion Criteria
  • Presence of invasive infection requiring intravenous antibiotics or debridement.
  • Significant reduced immunity or high dose corticosteroids (>10mg Prednisolone) or other second line immune-suppressant
  • Need for total contact cast
  • Patients with known or suspected malignancy in the wound or surrounding tissue.
  • Patients who are participating in another clinical study for peripheral vascular diseae wound management
  • Patients with a known history of poor compliance with medical treatment
  • Foot wounds
  • Diabetic patients who cannot have reliable ABI measurements.

Who cannot join

None listed.

Trial locations and contacts

No sites are listed yet.

About this study

Peripheral vascular disease (PVD) is a common disease of impaired blood flow resulting in the compromised tissue perfusion of lower limbs. PAD patients can experience pain, diminished exercise capacity, and tissue loss, with some ultimately requiring amputation. The economic burden of PVD is significant. In the United States alone, PVD accounts for over $20 billion in annual healthcare related costs.

The demand for the development of an effective method to characterize the viability of PVD wounds has resulted in the emergence of several innovative techniques. Commonly used diagnostic methods are ankle-brachial index (ABI), pulse volume recordings, duplex ultrasonography, venous plethysmography, Transcutaneous oxygen tension (TcPO2), toe pressures, angiography by X-ray, computed tomography, and magnetic resonance imaging. Currently, angiography remains the diagnostic gold standard. However, many of these techniques lack the ability to triage and adequately determine the viability of the wound. In addition, there remains a need for effective triage technologies to help clinicians decide whether surgical management is needed. Early determination of surgical versus conservative management may help to improve patient functional outcomes, reduce mortality rates, and prevent limb amputation.

Near-infrared point spectroscopy (NIRS) is a non-invasively technology with recent applications in PVD wound assessment. To date, studies have demonstrated the validity of NIRS technology in patients with peripheral arterial disease. NIRS measures flow, concentration, and oxygenation of hemoglobin in arterioles, capillaries, and venules several centimeters deep in tissue. The MSID is an evolution of existing NIRS imaging devices and has become a portable and functional commercial device produced by KENT imaging (Calgary, Canada). Using this new and clinically applicable NIRS technology designed for assessing wound perfusion and oxygenation, this study seeks to adequately identify viable from non-viable wounds and to rapidly determine indication for vascular interventions. This technology is well-suited for use in a wound patient population as the measurements times are short and can quickly be used at the patient bed side. As such, this project intends to apply NIR technology to quickly assess PVD in the investigators' patient population.

Read the detailed description

Peripheral vascular disease (PVD) is a common disease of the elderly, resulting in the compromise of blood flow to the lower limbs. As a consequence of impaired tissue perfusion, PAD patients can experience pain, diminished exercise capacity, and tissue loss, with some ultimately requiring amputation. Globally, lower extremity peripheral artery disease is the third leading cause of atherosclerotic cardiovascular morbidity, affecting over 200 million individuals worldwide. Peripheral vascular disease is becoming more prevalent with the increase of incidence with age and a globally aging population. In 2010, it was estimated that the number of people living with peripheral artery disease increased by 23.5% in the last decade. The economic burden of PVD is significant. In the United States alone, PVD accounts for over $20 billion in annual healthcare related costs. Specifically, non-healing wounds represent a significant portion of this expenditure at more than $3 billion per year.

The demand for the development of an effective method to characterize the viability of PVD wounds has resulted in the emergence of several innovative techniques. Commonly used diagnostic methods are ankle-brachial index (ABI), pulse volume recordings, duplex ultrasonography, venous plethysmography, angiography by X-ray, computed tomography, and magnetic resonance imaging. However, many of these techniques lack the ability to triage and adequately determine the viability of the wound. Ankle brachial index (ABI) is one of the most common screening techniques used to establish the presence of PVD, but it lacks sensitivity in creating sensitive and specific categorization of wounds as viable or non-viable. ABI gives an indication of a hemodynamically significant obstruction, but does not measure blood flow directly. Doppler ultrasound is another common method that can measure arterial blood flow, however some groups suggest that the femoral artery blood flow may not be an accurate hemodynamic indication of muscle ischemia. Magnetic resonance spectroscopy is also a new technique that has been validated in its application to assess PVD. Novel magnetic imaging sequences such as PIVOT (Perfusion, Intravascular Venous Oxygen Saturation) combine Blood Oxygen Level Dependent (BOLD) MRI and Arterial Spin Labeling (ASL) to comprehensively assess the tissue. Despite the strengths that many MRI techniques promise, clinical use limitations remain due to the high costs and availability of resources.

Peripheral vascular disease-induced lower extremity wounds have inadequate perfusion. Currently, there are three major approaches to improve vascular perfusion to the area: medical management, open surgery, and endovascular surgery. Medical management consists of lifestyle modification and management of associated risk factors such as smoking, diabetes mellitus, hyperlipidemia, hypertension, and hypercoagulability. While advances have been made in the medical management of lower extremity ischemia-induced wounds, large arterial revascularization remains the current standard of care. Open bypass surgery is often employed to bypass stenotic arteries and improve perfusion to lower extremity wounds. Over the last two decades, endovascular intervention has emerged as an additional therapy as it is minimally invasive and may have lower associated morbidity and mortality. In addition to improved perfusion of lower extremity wounds by medical management of surgical intervention, local wound care is required to expedite the healing process and prevent infection.

However, there remains a need for effective triage technologies to help clinicians decide whether surgical management is needed. This would allow for early determination of surgical versus conservative management and inpatient versus outpatient management. If surgery is required, patient functional outcomes are improved if it takes place earlier. As well, inpatient management of surgical patients is extremely costly. Outpatient management of patients with peripheral vascular wounds that do not require surgery would significantly reduce the costs associated with surgical intervention.

Near-infrared point spectroscopy (NIRS) non-invasively measures flow, concentration, and oxygenation of hemoglobin in arterioles, capillaries, and venules several centimeters deep in tissue. NIRS is safe and comfortable for patients and is well-suited to measure markers of viability in peripheral vascular disease wounds, including tissue perfusion, oxygenation and hemoglobin. To date, studies have demonstrated the validity of NIRS technology in patients with peripheral arterial disease. The Multi spectrum infrared device (MSID) represents an important evolution of existing NIRS imaging devices, which were designed for the clinical environment. The MSID has become a commercial device produced by KENT imaging (Calgary, Canada) after several animal and clinical trials have validated its use. The MSID is a new generation of NIR imaging devices with enhanced portability and functionality. The MSID is able to monitor many variables, such as cytochrome oxidase as a marker of tissue oxygen utilization, oxygen saturation, perfusion and methemoglobin as a marker of free radical injury. The advantage of the MSID is its capacity to account for skin colour. Melanin absorbs light and attenuates the amount of NIR light received by the camera. The Kent imaging device has unique mathematical algorithms to account for melanin content of the skin. In many previous studies done with NIRS technology in PVD wounds, melanin content was not considered to be a factor as patients demographic was predominantly Caucasian. However, in many multicultural cities where there is a wide variability in patient melanin content, melanin corrections in NIRS imaging are very important.

Using this new and clinically applicable NIRS technology designed for PVD, this study seeks to identify viable from non-viable wounds and to determine the severity of wound in assessing for vascular intervention indication. This technology is well-suited for use in a wound patient population as the measurements times are short and movement of subjects is not an issue. As such, this project intends to apply novel technology that has the capacity to quickly assess wounds as a complication of PVD.

Being tested
Multi-spectral Imaging Device (MSID)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Multi-spectral Imaging Device (MSID)Device

    Also called Near infrared spectroscopy (NIRS)

Study groups in NCT02624674
Study groupRoleWhat they receive
Multi-spectral Imaging GroupExperimentalAll subjects in this group will undergo baseline Near Infrared Spectroscopy (NIRS) measurement points with the Multi-spectral imaging device, baseline vascular studies (including ankle-brachial index (ABI), vascular doppler (arterial and venous), and toe pressures. At the one month mark (from baseline), NIR measurement point and vascular studies will again be performed. All measurements are incorporated into the routine wound care and will not require extra trips in hospital for wound care.
Receives: Device: Multi-spectral Imaging Device (MSID)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline in ABI (scale measurement)

    The Ankle-brachial index (ABI) result is used to predict the severity of peripheral vascular disease (PVD). The ankle-brachial index test compares blood pressure measured at the ankle with the blood pressure measured at the arm. ABI is measured on a scale from <0.5 to >1.5

    Measured: 1 month

  2. Change from baseline in Vascular Doppler (imaging analysis)

    Doppler ultrasound is a special ultrasound technique that uses sound waves to non-invasively evaluate the blood flow through arteries and veins in the body. Blood flow measurements from vascular doppler are measured in mL/min.

    Measured: 1 month

  3. Change from baseline in Toe pressures (physiological parameter measurement)

    Toe pressures are non-invasive blood pressure measurements taken at the toe and measured in mmHg.

    Measured: 1 month

  4. Change from baseline in Angiography (imaging analysis)

    Angiography or arteriography is a x-ray medical imaging technique used to visualize the inside (lumen) of blood vessels and organs in the body. Analysis is given by imaging experts (i.e., radiologists, cardiologists, or technologists) in a descriptive report.

    Measured: 1 month

  5. Change from baseline in Oxygen saturation from the MSID device (scale measurement)

    Using visible and near infrared light, oxygen saturation can non-invasively be determined from using the MSID device. Oxygen saturation is measured in percentage from 0-100%.

    Measured: 1 month

  6. Change from baseline in Total hemoglobin from the MSID device (physiological parameter measurement)

    Using visible and near infrared light, total hemoglobin can non-invasively be determined from using the MSID device. Total hemoglobin is measured by g/L.

    Measured: 1 month

  7. Change from baseline in Wound Healing (physiological parameter measurement)

    Wound healing is determined by the amount of change in the wound surface area (measured in mm^2)

    Measured: 1 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Dec 2015 (estimated)
  2. Study startDec 2015
  3. Primary completionDec 2016 (estimated)
  4. Study completionDec 2016 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02624674
Sponsor's protocol ID
15-249c
Status last verified
Dec 2015
First submitted
13 Aug 2015
Last updated
8 Dec 2015
Results posted
No
Data monitoring committee
No

Publications

  • Kramer CM. Skeletal muscle perfusion in peripheral arterial disease a novel end point for cardiovascular imaging. JACC Cardiovasc Imaging. 2008 May;1(3):351-3. doi: 10.1016/j.jcmg.2008.03.004.

    PubMed 19356448
  • Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013 Oct 19;382(9901):1329-40. doi: 10.1016/S0140-6736(13)61249-0. Epub 2013 Aug 1.

    PubMed 23915883
  • McDermott MM. Peripheral arterial disease: epidemiology and drug therapy. Am J Geriatr Cardiol. 2002 Jul-Aug;11(4):258-66. doi: 10.1111/j.1076-7460.2002.00031.x.

    PubMed 12091774
  • Menke NB, Ward KR, Witten TM, Bonchev DG, Diegelmann RF. Impaired wound healing. Clin Dermatol. 2007 Jan-Feb;25(1):19-25. doi: 10.1016/j.clindermatol.2006.12.005.

    PubMed 17276197
  • Bernink, P. J. L. M., Lubbers, J., Barendsen, G. J., and Van den try in the assessment of peripheral arterial disease. Adv. Exp.

  • Lewis P, Psaila JV, Morgan RH, Davies WT, Woodcock JP. Common femoral artery volume flow in peripheral vascular disease. Br J Surg. 1990 Feb;77(2):183-7. doi: 10.1002/bjs.1800770220.

    PubMed 2317678
  • Zatina MA, Berkowitz HD, Gross GM, Maris JM, Chance B. 31P nuclear magnetic resonance spectroscopy: noninvasive biochemical analysis of the ischemic extremity. J Vasc Surg. 1986 Mar;3(3):411-20. doi: 10.1067/mva.1986.avs0030411.

    PubMed 2936903
  • Kramer CM. Novel magnetic resonance imaging end points for physiologic studies in peripheral arterial disease: elegance versus practicality. Circ Cardiovasc Imaging. 2015 Apr;8(4):10.1161/CIRCIMAGING.115.003360 e003360. doi: 10.1161/CIRCIMAGING.115.003360. No abstract available.

    PubMed 25873725
  • Bunte MC, Shishehbor MH. Treatment of infrapopliteal critical limb ischemia in 2013: the wound perfusion approach. Curr Cardiol Rep. 2013 Jun;15(6):363. doi: 10.1007/s11886-013-0363-5.

    PubMed 23605465
  • Romiti M, Albers M, Brochado-Neto FC, Durazzo AE, Pereira CA, De Luccia N. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008 May;47(5):975-981. doi: 10.1016/j.jvs.2008.01.005. Epub 2008 Apr 18.

    PubMed 18372148
  • Cross, K. M. 2010. Assessing tissue viability of acute thermal injuries using near infrared point spectroscopy.

  • Cross KM, Leonardi L, Gomez M, Freisen JR, Levasseur MA, Schattka BJ, Sowa MG, Fish JS. Noninvasive measurement of edema in partial thickness burn wounds. J Burn Care Res. 2009 Sep-Oct;30(5):807-17. doi: 10.1097/BCR.0b013e3181b485e9.

    PubMed 19692905
  • Cross KM, Leonardi L, Payette JR, Gomez M, Levasseur MA, Schattka BJ, Sowa MG, Fish JS. Clinical utilization of near-infrared spectroscopy devices for burn depth assessment. Wound Repair Regen. 2007 May-Jun;15(3):332-40. doi: 10.1111/j.1524-475X.2007.00235.x.

    PubMed 17537120
  • Leonardi L, Sowa MG, Payette JR, Mantsch HH. Near-infrared spectroscopy and imaging: a new approach to assess burn injuries. Am Clin Lab. 2000 Sep-Oct;19(8):20-2. No abstract available.

    PubMed 11146988
  • Sowa MG, Leonardi L, Payette JR, Cross KM, Gomez M, Fish JS. Classification of burn injuries using near-infrared spectroscopy. J Biomed Opt. 2006 Sep-Oct;11(5):054002. doi: 10.1117/1.2362722.

    PubMed 17092151

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Multi-spectral Imaging Device (MSID) in people with Peripheral Vascular Disease Patient, run by Unity Health Toronto.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 8 Dec 2015. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Janelle Yu, Bsc (4167971536, janelle.yu@mail.utoronto.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline in ABI (scale measurement) (time frame: 1 month). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02624674, which also lists 20 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Dec 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in